news flash·2025-06-30 09:11Core Viewpoint - Xinhua Pharmaceutical (000756) has received approval from the National Medical Products Administration for the registration certificate of Ivabradine Hydrochloride Tablets, indicating a significant advancement in its product portfolio [1] Group 1: Product Approval - The full subsidiary Shandong Zibo Xinda Pharmaceutical Co., Ltd. has been granted the drug registration certificate for Ivabradine Hydrochloride Tablets [1] - This medication is indicated for patients with chronic heart failure of NYHA II-IV class, who have sinus rhythm and a heart rate of ≥75 beats per minute, and is to be used in conjunction with standard treatments including beta-blockers or when beta-blockers are contraindicated or not tolerated [1] Group 2: Market Potential - The estimated sales revenue for Ivabradine Hydrochloride Tablets in urban public medical institutions in China is approximately 350 million yuan in 2024 [1]